Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 25-31

  Delgado, Elena ^a   Fernández García, Aurora ^a   Vega, Yolanda ^a   Cuevas, Teresa ^a   Pinilla, Milagros ^a   García, Valentina ^a   Sánchez, Mónica ^a   González, Marí ^a   Sánchez, Ana María ^a   Thomson, Michael M ^a   Pérez Álvarez, Lucía ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

CCR5; CXCR4; Maraviroc; Sensitivity; Specificity; V3

Indexed keywords

ARTICLE; CONTROLLED STUDY; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIVITY AND SPECIFICITY; VIRAL TROPISM; VIRUS DETECTION; CELL CULTURE; EVALUATION; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PATHOGENICITY; VIROLOGY; VIRUS ATTACHMENT;

VIRUS RECEPTOR;

CELLS, CULTURED; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, HIV; SENSITIVITY AND SPECIFICITY; VIRAL TROPISM; VIROLOGY; VIRUS ATTACHMENT;

EID: 84859168636     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr438     Document Type: Article

References (49)

1. Berger EA, Doms RW, Fenyö EM et al. A new classification for HIV-1. Nature 1998; 391: 240.
2. Abebe A, Demissie D, Goudsmit J et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999; 13: 1305-11.
3. Cilliers T, Nhlapo J, Coetzer M et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77: 4449-56.
4. Connel BJ, Michler K, Capovilla A et al. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 2008; 22: 896-9.
5. Neogi U, Prarthana SB, D'Souza G et al. Co-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: therapeutic implications for India. AIDS Res Ther 2010; 7: 24.
6. Kaleebu P, Nankya IL, Yirrell DL et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45: 28-33.
7. Huang W, Eshleman SH, Toma J et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81: 7885-93.
8. Pérez-Álvarez L, Muñoz M, Delgado E et al. Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain. J Med Virol 2006; 78: 1520-8.
9. Pérez-Álvarez L, Delgado E, Villahermosa ML et al. Biological characteristics of newly described HIV-1 BG recombinants in Spanish individuals. AIDS 2002; 16: 669-72.
10. Esbjörnsson J, Månsson F, Martínez-Arias W et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 2010; 7: 23.
11. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
12. Björndal A, Deng H, Jansson M et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-87.
13. Bleul CC, Wu L, Hoxie JA et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94: 1925-30.
14. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
15. Trinh L, Han D, Huang W et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antivir Ther 2008; 13 Suppl 3: A128.
16. Braun P, Wiesmann F. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur J Med Res 2007; 12: 463-72.
17. Low AJ, Swenson LC, Harrigan PR. HIV coreceptor phenotyping in the clinical setting. AIDS Rev 2008; 10: 143-51.
18. Rose JD, Rhea AM, Weber J et al. Current tests to evaluate HIV-1 coreceptor tropism. Curr Opin HIV AIDS 2009; 4: 136-42.
19. Raymond S, Delobel P, Mavigner M et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010; 47: 126-30.
20. González N, Pérez-Olmeda M, Mateos E et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother 2010; 65: 2493-501.
21. Reeves D, Coakley E, Petropoulos CJ et al. An enhanced-sensitivity TrofileTM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009; 3: 94-102.
22. Boyd MT, Simpson GR, Cann AJ et al. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 1993; 67: 3649-52.
23. Carrillo A, Ratner L. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 1996; 70: 1301-9.
24. Groenink M, Fouchier RA, Broersen S et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993; 260: 1513-6.
25. Fouchier RA, Groenink M, Kootstra NA et al. Phenotype-associated sequence variation of the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66: 3183-7.
26. Delobel P, Nugeyre MT, Cazabat M et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007; 45: 1572-80.
27. Chueca N, Garrido C, Alvarez M et al. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 2009; 81: 763-7.
28. Lengauer T, Sander O, Sierra S et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10.
29. Pillai S, Good B, Richman D et al. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19: 145-9.
30. Jensen MA, Li FS, van't Wout AB et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
31. Raymond S, Delobel P, Mavigner M et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009; 47: 2292-4.
32. Seclén E, Garrido C, González M et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010; 65: 1486-92.
33. Raymond S, Delobel P, Mavigner M et al. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 2010; 3: 167-75.
34. Garrido C, Roulet V, Chueca N et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different immunodefici ency virus type 1 subtypes. J Clin Microbiol 2008; 46: 887-91.
35. Fernández-Garcí A, Cuevas MT, Muñoz-Nieto M et al. Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses 2009; 25: 93-102.
36. Cuevas MT, Fernández-García A, Pinilla M et al. Biological and genetic characterization of HIV type 1 subtype B and nonsubtype B transmitted viruses: usefulness for vaccine candidate assessment. AIDS Res Hum Retroviruses 2010; 26: 1019-25.
37. Hollinger FB, Bremer JW, Myers LE et al. Standardization of sensitive human immunodeficiency virus coculture procedures and establish ment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol 1992; 30: 1787-94.
38. Delgado E, Thomson MM, Villahermosa ML et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002; 29: 536-43.
39. Delwart EL, Shpaer EG, Louwagie J et al. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 1993; 262: 1257-61.
40. Poveda E, Alcamí J, Paredes R et al. Genotypic determination of HIV tropism-clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010; 12: 135-48.
41. Recordon-Pinson P, SouliéC, Flandre P et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 2010; 54: 3335-40.
42. Low AJ, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: 17-24.
43. Raymond S, Delobel P, Mavigner M et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22: 11-6.
44. Ragupathy V, Zhao J, Wang X et al. Comparative analysis of cell culture and prediction algorithms for phenotyping of genetically diverse HIV-1 strains from Cameroon. AIDS Res Ther 2009; 6: 27.
45. Poveda E, Seclén E, González M et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009; 63: 1006-10.
46. Skrabal K, Low AJ, Dong W et al. Determining human immunode ficiency virus coreceptor usage in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45: 279-84.
47. Delgado E, Pérez-Á lvarez L, Vega Y et al. Phylogenetic transmission in men having sex with men in Spain, including subtypes: B, F1, CRF02_AG and BG recombinants. In: Abstracts of the Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, 2010. Abstract MOPE041. http://pag.ias2011.org/Abstracts. aspx?AID=4177.
48. Holm-Hansen C, Baan E, Asjö B et al. Determinants for the syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 region. AIDS Res Hum Retroviruses 2000; 16: 867-70.
49. Sánchez V, Pharm D, Masiá M et al. A highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining interpretation of V3 loop sequences and clinical parameters. J Acquir Immune Defic Syndr 2011; 56: 51-8.